Dynavax Technologies (NASDAQ:DVAX) plummets on concerns that Heplisav approval could be delayed

  on Nov 19,2012 Posted in Business News ,Finance
Share |
We're on   

Dynavax Technologies Corporation (NASDAQ:DVAX) lost about 50 percent on Friday after a government advisory panel raised a question on the safety of its most advanced drug candidate, Heplisav. The company said a Food and Drug Administration panel provided an opinion saying clinical trial data was unable to prove Heplisav is safe. The majority of the panelists decided that patients’ immune systems responded to the drug.

The Berkeley, Calif., company claims that Heplisav could outperform other hepatitis B vaccines. The FDA is planned to make a decision on the experimental hepatitis B vaccine by Feb. 24. The agency is not bound to pursue the advice of its panels, but if often does so. If the agency holds the same opinion as the panel, the approval of Heplisav could be postponed as Dynavax looks for more data to establish the safety of the drug.

With market capitalization of $436.05 million, Dynavax Technologies Corporation (NASDAQ:DVAX) shares were trading within the range of $2.22-$2.58 while its opening price was $2.30. DVAX’s 5 years revenue rate remained 34.85% while its current ratio was 5.26 and debt to equity was 0.11. Its return on investment was -56.46%.

DVAX belongs to Healthcare sector with industry of Drug Manufacturers and its archrivals include Amarin and Warner Chilcott. Let’s have a look over opponents’ performance.

Amarin Corporation plc (ADR) (NASDAQ:AMRN) fell -3.56% to $10.84 with the total traded volume of 7.83 million shares and Warner Chilcott Plc (NASDAQ:WCRX) surged 1.53% to $11.98 with the total traded volume of 6.24 million shares.

DVAX is lagging behind from its 52 weeks high price with -54.31%. DVAX’s last month’s stock price volatility remained 6.65%. The stock price of DVAX is moving down from its 20 days moving average with -43.33% and remote negatively from 50 days moving average with -45.98%.

DVAX’s current year earnings per share got a lift of 44.10% while its current quarter performance stayed at -35.79%. Company’s beta coefficient included 2.87. Beta factor calculates the amount of market risk linked with market trade.



Leave a Reply